Jason Ehrlich - Aug 20, 2021 Form 4 Insider Report for Kodiak Sciences Inc. (KOD)

Role
Chief Medical Officer and Chief Development Officer
Signature
/s/ David Peinsipp, Attorney-in-Fact for Jason Ehrlich
Stock symbol
KOD
Transactions as of
Aug 20, 2021
Transactions value $
-$581,429
Form type
4
Date filed
8/24/2021, 04:59 PM
Previous filing
Aug 13, 2021
Next filing
Sep 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KOD Common Stock Options Exercise $54.1K +5.26K +9.88% $10.29 58.5K Aug 20, 2021 Direct
transaction KOD Common Stock Sale -$35.6K -404 -0.69% $88.17* 58.1K Aug 20, 2021 Direct F1, F2
transaction KOD Common Stock Sale -$45.4K -510 -0.88% $89.06* 57.6K Aug 20, 2021 Direct F1, F3
transaction KOD Common Stock Sale -$49.1K -542 -0.94% $90.64* 57K Aug 20, 2021 Direct F1, F4
transaction KOD Common Stock Sale -$292K -3.19K -5.6% $91.60* 53.8K Aug 20, 2021 Direct F1, F5
transaction KOD Common Stock Sale -$211K -2.28K -4.23% $92.52* 51.6K Aug 20, 2021 Direct F1, F6
transaction KOD Common Stock Sale -$2.14K -23 -0.04% $93.04* 51.5K Aug 20, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KOD Stock Option (Right to Buy) Options Exercise $0 -5.26K -2.03% $0.00 253K Aug 20, 2021 Common Stock 5.26K $10.29 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $87.66 to $88.40, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.
F3 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $88.81 to $89.78, inclusive.
F4 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $89.945 to $90.94, inclusive.
F5 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $91.10 to $91.995, inclusive.
F6 The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $92.02 to $92.995, inclusive.
F7 Twenty-five percent of the shares subject to the option vested on September 1, 2019, and 1/48th of the shares subject to the option vest on the same day of each month thereafter.

Remarks:

Chief Medical Officer and Chief Development Officer